Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Market Cap	$1.54B	P/E Ratio	N/A
52W High	$40.72	52W Low	$23.15
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	30.1%	52W Position	50.4%
Overall Score	10	Value Score	--
Quality Score	--	Technical Score	10

EPS Current Est	$-0.97	EPS Next Est	$-0.39
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IMCR	$32.00	+0.13%	356.64K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IMCR	$32.00	+0.1%	356.64K
3
4
5
6

IMCR

IMCR

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Immunocore Holdings plc Data in Excel

Get Immunocore Holdings plc Data in Excel